Congenital CMV: Difference between revisions
From IDWiki
Content deleted Content added
No edit summary |
|||
| Line 32: | Line 32: | ||
** Hearing |
** Hearing |
||
** Eye |
** Eye |
||
* IV ganciclovir or PO valganciclovir, for 6 months |
* IV [[Is treated by::ganciclovir]] or PO [[Is treated by::valganciclovir]], for 6 months |
||
* Monitor CBC while on therapy |
* Monitor CBC while on therapy |
||
Revision as of 02:26, 24 October 2019
Epidemiology
- Risk of transmission to fetus
- Primary infection: 30% risk of congenital CMV; higher risk later in pregnancy, but worse outcomes earlier
- Non-primary
- Reinfection: 5% risk
- Reactivation: 1% risk
Clinical Presentation
- At birth
- Microcephaly
- Periventricular calcifications
- Chorioretinitis
- Sensorineural hearing loss
- Optic nerve atrophy
- Hepatosplenomegaly
- Cytopenia
- Later
- Cognitive deficits (7%)
- Sensorineural hearing loss (20%)
Diagnosis
- In mom, IgM antibodies
- In baby, urine PCR within 2 weeks of birth
Management
- Treatment is indicated for symptomatic babies
- Brain
- Hearing
- Eye
- IV ganciclovir or PO valganciclovir, for 6 months
- Monitor CBC while on therapy
